Subjects with pre‑existing cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. the study included 9713 overweight or obese subjects with preexisting cardiovascular disease and/ or type 2 diabetes. the subjects were randomly assigned to subitramine ( 4997 subjects) or a placebo ( 4716 subjects) in a double‑blind fashion. the primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. the primary outcome was observed in 581 subjects in the subitramine group and 474 subjects in the placebo group. do the data give good reason to think that there is a difference between the proportions of treatment and placebo subjects who experienced the primary outcome? (a) state hypotheses, find the test statistic and use either software or the bottom row of table a for the ‑value. test statistic =